RKL Wealth Management LLC grew its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 21.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 23,885 shares of the medical equipment provider’s stock after buying an additional 4,250 shares during the period. RKL Wealth Management LLC’s holdings in Hologic were worth $875,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds also recently modified their holdings of HOLX. Parnassus Investments CA bought a new position in Hologic during the third quarter worth about $277,062,000. Capital World Investors bought a new stake in Hologic in the 2nd quarter valued at $312,441,000. HealthCor Management L.P. bought a new stake in Hologic in the 2nd quarter valued at $76,604,000. Columbus Circle Investors bought a new stake in shares of Hologic during the 2nd quarter valued at $54,511,000. Finally, Vanguard Group Inc. lifted its position in shares of Hologic by 4.2% during the 2nd quarter. Vanguard Group Inc. now owns 29,547,138 shares of the medical equipment provider’s stock valued at $1,340,850,000 after acquiring an additional 1,200,825 shares during the period. Hedge funds and other institutional investors own 96.41% of the company’s stock.
HOLX has been the subject of a number of recent analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $50.00 target price on shares of Hologic in a research report on Monday, October 2nd. Deutsche Bank AG cut their target price on Hologic from $51.00 to $49.00 and set a “buy” rating for the company in a research report on Thursday, August 3rd. Royal Bank Of Canada cut their target price on Hologic from $50.00 to $45.00 and set a “sector perform” rating for the company in a research report on Thursday, August 3rd. Piper Jaffray Companies reiterated a “buy” rating and set a $48.00 target price on shares of Hologic in a research report on Thursday, November 9th. Finally, Barclays PLC cut their target price on Hologic from $53.00 to $51.00 and set an “overweight” rating for the company in a research report on Thursday, August 3rd. One analyst has rated the stock with a sell rating, five have given a hold rating and nine have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $47.54.
Shares of Hologic, Inc. (NASDAQ HOLX) traded up $0.34 during mid-day trading on Thursday, hitting $39.59. The company had a trading volume of 494,108 shares, compared to its average volume of 2,748,644. The company has a current ratio of 0.79, a quick ratio of 0.61 and a debt-to-equity ratio of 0.78. Hologic, Inc. has a twelve month low of $35.76 and a twelve month high of $46.80. The company has a market cap of $10,902.37, a P/E ratio of 19.61, a P/E/G ratio of 1.92 and a beta of 0.93.
Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.49 by $0.01. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The business had revenue of $802.90 million during the quarter, compared to analysts’ expectations of $792.54 million. During the same quarter in the prior year, the firm earned $0.52 EPS. The business’s revenue for the quarter was up 10.5% compared to the same quarter last year. analysts anticipate that Hologic, Inc. will post 2.12 EPS for the current year.
In other Hologic news, Director Elaine Ullian sold 9,282 shares of the company’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $40.50, for a total value of $375,921.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Lawrence M. Levy sold 9,596 shares of the company’s stock in a transaction dated Tuesday, October 10th. The stock was sold at an average price of $36.81, for a total value of $353,228.76. The disclosure for this sale can be found here. In the last ninety days, insiders sold 34,949 shares of company stock valued at $1,345,220. Insiders own 0.79% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://ledgergazette.com/2017/11/16/hologic-inc-holx-holdings-boosted-by-rkl-wealth-management-llc.html.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.